Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases

被引:0
作者
Vidul Goenka
Tanhai Borkar
Aska Desai
Raunak Kumar Das
机构
[1] Vellore Institute of Technology,School of Biosciences and Technology
[2] Vellore Institute of Technology,Centre for Biomaterials, Cellular and Molecular Theranostics
来源
Journal of Diabetes & Metabolic Disorders | 2020年 / 19卷
关键词
Diabetes-associated diseases; Immunomodulation; Immunosuppression; Insulin-producing cells; Insulin resistance; Mesenchymal stem cells;
D O I
暂无
中图分类号
学科分类号
摘要
Diabetes mellitus is a common lifestyle disease which can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus. While both result in hyperglycemia due to lack of insulin action and further associated chronic ailments, there is a marked distinction in the cause for each type due to which both require a different prophylaxis. As observed, type 1 diabetes is caused due to the autoimmune action of the body resulting in the destruction of pancreatic islet cells. On the other hand, type 2 diabetes is caused either due to insulin resistance of target cells or lack of insulin production as per physiological requirements. Attempts to cure the disease have been made by bringing drastic changes in the patients’ lifestyle; parenteral administration of insulin; prescription of drugs such as biguanides, meglitinides, and amylin; pancreatic transplantation; and immunotherapy. While these attempts cause a certain degree of relief to the patient, none of these can cure diabetes mellitus. However, a new treatment strategy led by the discovery of mesenchymal stem cells and their unique immunomodulatory and multipotent properties has inspired therapies to treat diabetes by essentially reversing the conditions causing the disease. The current review aims to enumerate the role of various mesenchymal stem cells and the different approaches to treat both types of diabetes and its associated diseases as well.
引用
收藏
页码:1979 / 1993
页数:14
相关论文
共 881 条
[1]  
Staffers DA(1997)Early-onset type-ll diabetes mellitus (MODY4) linked to IPF1 Nat Genet 17 138-139
[2]  
Ferrer J(2006)Incidence and trends of childhood type 1 diabetes worldwide 1990–1999 Diabet Med 23 857-866
[3]  
Clarke WL(2009)Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study Lancet (London, England) 373 2027-2033
[4]  
Habener JF(2015)Recent trends in therapeutic approaches for diabetes management: a comprehensive update J Diabetes Res 2015 340838-340811
[5]  
Patterson CC(2016)Update on the treatment of type 2 diabetes mellitus World J Diabetes 7 354-395
[6]  
Dahlquist GG(2012)Diabetes treatment in 2025: can scientific advances keep pace with prevalence? Ther Adv Endocrinol Metab 3 163-173
[7]  
Gyurus E(2008)Mesenchymal stem cells - sources and clinical applications Transfus Med Hemother 35 272-277
[8]  
Green A(2011)Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC Cell Commun Signal 9 12-640
[9]  
Soltesz G(2008)Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice Biol Blood Marrow Transplant 14 631-596
[10]  
Tiwari P(2010)Mesenchymal stromal cells: current understanding and clinical status Stem Cells 28 585-38